Nextage Therapeutics Ltd - Asset Resilience Ratio
Nextage Therapeutics Ltd (NXTG) has an Asset Resilience Ratio of 2.32% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check NXTG capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2021)
This chart shows how Nextage Therapeutics Ltd's Asset Resilience Ratio has changed over time. See NXTG equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Nextage Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Nextage Therapeutics Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA99.00K | 2.32% |
| Total Liquid Assets | ILA99.00K | 2.32% |
Asset Resilience Insights
- Limited Liquidity: Nextage Therapeutics Ltd maintains only 2.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nextage Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Nextage Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Hainan Haiyao Co Ltd
SHE:000566 |
Drug Manufacturers - Specialty & Generic | 3.27% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Nextage Therapeutics Ltd (2017–2021)
The table below shows the annual Asset Resilience Ratio data for Nextage Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 2.32% | ILA99.00K ≈ $265.42 |
ILA4.27 Million ≈ $11.45K |
+1.46pp |
| 2020-12-31 | 0.86% | ILA35.00K ≈ $93.83 |
ILA4.07 Million ≈ $10.91K |
-1.17pp |
| 2019-12-31 | 2.03% | ILA122.00K ≈ $327.08 |
ILA6.01 Million ≈ $16.10K |
-0.20pp |
| 2018-12-31 | 2.23% | ILA122.00K ≈ $327.08 |
ILA5.48 Million ≈ $14.68K |
+1.24pp |
| 2017-12-31 | 0.98% | ILA122.00K ≈ $327.08 |
ILA12.39 Million ≈ $33.23K |
-- |
About Nextage Therapeutics Ltd
Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.